Pfizer (NYSE:PFE) Stock Rating Upgraded by Zacks Research

Pfizer (NYSE:PFE) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other analysts have also issued reports on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Morgan Stanley decreased their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Finally, Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $27.70.

Pfizer Stock Down 0.1%

Shares of NYSE:PFE opened at $27.11 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $154.11 billion, a P/E ratio of 19.93 and a beta of 0.47. Pfizer has a 52-week low of $20.92 and a 52-week high of $27.94. The stock’s fifty day simple moving average is $26.04 and its 200-day simple moving average is $25.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 EPS. As a group, equities research analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Hedge funds have recently made changes to their positions in the business. Triad Wealth Partners LLC lifted its stake in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares in the last quarter. ETF Store Inc. raised its holdings in shares of Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the period. Mattern Wealth Management LLC lifted its position in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares in the last quarter. Pines Wealth Management LLC boosted its holdings in Pfizer by 4.4% in the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares during the period. Finally, Peak Asset Management LLC grew its position in Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to the BRAFTOVI (encorafenib) combination regimen for first‑line metastatic colorectal cancer with BRAF V600E mutation — a label expansion based on the Phase 3 BREAKWATER trial that de‑risks and commercializes a late‑stage oncology asset, supporting potential incremental sales and long‑term oncology upside. U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
• Positive Sentiment: Pfizer inks a China commercialization/licensing deal for Sciwind’s ecnoglutide (a next‑gen biased GLP‑1) with up to ~$495M in potential payments — accelerates Pfizer’s obesity/diabetes footprint in a large market and signals management’s push into metabolic medicines beyond acquisitions. Pfizer in diabetes drug deal with Sciwind Biosciences
• Positive Sentiment: Pipeline momentum: coverage notes highlight BREAKWATER results plus expanded obesity programs (Metsera acquisition and >20 weight‑management studies) — suggests diversification of future growth drivers beyond legacy products. Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results
• Positive Sentiment: Dividend support: coverage reiterates Pfizer’s high dividend yield (attractive income for some investors) and management’s commitment to the payout, which can cushion the stock in choppy markets. This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
• Neutral Sentiment: Pneumococcal vaccine Phase 1 update in China — an early‑stage readout that is informational for the pipeline but unlikely to move top‑line revenue in the near term. Pfizer’s Pneumococcal Vaccine Study in China: What the Latest Trial Update Means for PFE Investors
• Neutral Sentiment: Valuation and performance write‑ups debate whether PFE is offering value after mixed multi‑year returns — useful context for long‑term investors but not an immediate catalyst. Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance
• Negative Sentiment: Pfizer terminated a Phase 1b ulcerative colitis study — a setback for that early‑stage program and a reminder of R&D risk; impact on revenue is limited but it trims future optionality in immunology. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study: What Investors Should Watch
• Negative Sentiment: Analyst caution: commentary that Pfizer has underperformed the healthcare sector over the past year could pressure sentiment and limit upside until clearer organic growth or margin inflection is visible. Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.